Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.07
DGX's Cash to Debt is ranked lower than
93% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. DGX: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
DGX' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.08 Max: N/A
Current: 0.07
Equity to Asset 0.45
DGX's Equity to Asset is ranked lower than
73% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. DGX: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
DGX' s Equity to Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.44 Max: 0.62
Current: 0.45
0.3
0.62
Interest Coverage 10.91
DGX's Interest Coverage is ranked lower than
69% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 96.50 vs. DGX: 10.91 )
Ranked among companies with meaningful Interest Coverage only.
DGX' s Interest Coverage Range Over the Past 10 Years
Min: 5.74  Med: 7.97 Max: 11.69
Current: 10.91
5.74
11.69
F-Score: 7
Z-Score: 3.37
M-Score: -2.46
WACC vs ROIC
5.68%
11.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.66
DGX's Operating margin (%) is ranked higher than
86% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. DGX: 20.66 )
Ranked among companies with meaningful Operating margin (%) only.
DGX' s Operating margin (%) Range Over the Past 10 Years
Min: 13.22  Med: 17.22 Max: 20.66
Current: 20.66
13.22
20.66
Net-margin (%) 11.03
DGX's Net-margin (%) is ranked higher than
79% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.52 vs. DGX: 11.03 )
Ranked among companies with meaningful Net-margin (%) only.
DGX' s Net-margin (%) Range Over the Past 10 Years
Min: 5.07  Med: 8.69 Max: 11.88
Current: 11.03
5.07
11.88
ROE (%) 18.17
DGX's ROE (%) is ranked higher than
86% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. DGX: 18.17 )
Ranked among companies with meaningful ROE (%) only.
DGX' s ROE (%) Range Over the Past 10 Years
Min: 10.72  Med: 16.28 Max: 20.93
Current: 18.17
10.72
20.93
ROA (%) 8.28
DGX's ROA (%) is ranked higher than
82% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. DGX: 8.28 )
Ranked among companies with meaningful ROA (%) only.
DGX' s ROA (%) Range Over the Past 10 Years
Min: 4.78  Med: 7 Max: 10.69
Current: 8.28
4.78
10.69
ROC (Joel Greenblatt) (%) 110.52
DGX's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.24 vs. DGX: 110.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DGX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 88.63  Med: 117.16 Max: 143.99
Current: 110.52
88.63
143.99
Revenue Growth (3Y)(%) 3.80
DGX's Revenue Growth (3Y)(%) is ranked lower than
53% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.20 vs. DGX: 3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DGX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 8.1 Max: 15.4
Current: 3.8
0
15.4
EBITDA Growth (3Y)(%) 4.20
DGX's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. DGX: 4.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DGX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.3 Max: 44.4
Current: 4.2
0
44.4
EPS Growth (3Y)(%) 7.50
DGX's EPS Growth (3Y)(%) is ranked higher than
66% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. DGX: 7.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DGX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.4 Max: 61.5
Current: 7.5
0
61.5
» DGX's 10-Y Financials

Financials (Next Earnings Date: 2016-10-20)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

DGX Guru Trades in Q3 2015

Scott Black 111,006 sh (New)
Ray Dalio 236,592 sh (+236.12%)
Joel Greenblatt 600,031 sh (+113.30%)
Jim Simons 107,620 sh (+98.56%)
John Rogers 695,732 sh (+19.84%)
Murray Stahl 7,550 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Jeff Auxier 72,820 sh (-0.21%)
David Dreman 19,914 sh (-0.29%)
Charles Brandes 170,422 sh (-1.11%)
Paul Tudor Jones 17,360 sh (-2.30%)
Chris Davis 4,203,791 sh (-15.59%)
John Hussman 127,000 sh (-36.50%)
Pioneer Investments 216,947 sh (-59.18%)
» More
Q4 2015

DGX Guru Trades in Q4 2015

Pioneer Investments 220,556 sh (+1.66%)
Bernard Horn 61,733 sh (unchged)
Jim Simons Sold Out
John Rogers 693,253 sh (-0.36%)
Charles Brandes 168,985 sh (-0.84%)
David Dreman 19,614 sh (-1.51%)
Murray Stahl 7,350 sh (-2.65%)
Jeff Auxier 70,270 sh (-3.50%)
Chris Davis 3,590,857 sh (-14.58%)
Paul Tudor Jones 10,548 sh (-39.24%)
Joel Greenblatt 270,275 sh (-54.96%)
Scott Black 35,253 sh (-68.24%)
Ray Dalio 64,399 sh (-72.78%)
John Hussman 2,000 sh (-98.43%)
» More
Q1 2016

DGX Guru Trades in Q1 2016

John Rogers 747,094 sh (+7.77%)
John Hussman 2,000 sh (unchged)
Murray Stahl 7,350 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Ray Dalio Sold Out
Jeff Auxier 69,955 sh (-0.45%)
Charles Brandes 162,685 sh (-3.73%)
Chris Davis 3,314,772 sh (-7.69%)
Joel Greenblatt 249,221 sh (-7.79%)
Scott Black 31,347 sh (-11.08%)
David Dreman 14,059 sh (-28.32%)
Paul Tudor Jones 6,786 sh (-35.67%)
Pioneer Investments 123,162 sh (-44.16%)
» More
Q2 2016

DGX Guru Trades in Q2 2016

Pioneer Investments 184,754 sh (+50.01%)
Jeff Auxier 69,955 sh (unchged)
Bernard Horn 61,733 sh (unchged)
John Hussman 2,000 sh (unchged)
Murray Stahl 7,300 sh (-0.68%)
Chris Davis 3,279,494 sh (-1.06%)
David Dreman 13,474 sh (-4.16%)
Scott Black 30,000 sh (-4.30%)
Charles Brandes 146,794 sh (-9.77%)
Paul Tudor Jones 6,000 sh (-11.58%)
Joel Greenblatt 177,438 sh (-28.80%)
John Rogers 454,535 sh (-39.16%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:IDXX, OTCPK:SSMXY, NYSE:LH, NYSE:Q, NYSE:A, NAS:DXCM, OTCPK:ERFSF, NAS:QGEN, NYSE:PKI, OTCPK:BMXMF, NYSE:BIO, NAS:ICLR, NYSE:CRL, NAS:VWR, NAS:PRXL, NAS:BRKR, OTCPK:DSRLF, NYSE:ALR, NAS:PRAH, OTCPK:SWTUY » details
Traded in other countries:QDI.Germany,
Quest Diagnostics Inc is the provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Quest Diagnostics Inc was incorporated in Delaware in 1990. The Company and its subsidiaries are the providers of diagnostic testing. The Company operations are organized in two business groups; Diagnostics Information Services and Diagnostic Solutions group. The Diagnostics Information Services business is a provider of diagnostic information services, which includes providing clinical testing services such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing, as well as related services and insights. The Company offers patients, physicians, hospitals, IDNs, health plans, employers and others the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, Company-owned patient service centers and phlebotomists in physician offices. It provides interpretive consultation through the medical and scientific staff in the industry, including over 725 M.D.s and Ph.D.s, located in the United States, many of whom are recognized leaders in their fields, and genetic counselors. Diagnostic Solutions group offers solutions for insurers, healthcare providers and others. The Company is a provider of risk assessment services for the life insurance industry. The Company is a provider of testing for clinical trials. In addition, it offers healthcare organizations and clinicians robust information technology solutions and diagnostic products, including test kits. The Company is subject to or impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and the other jurisdictions in which it conducts business.

Ratios

vs
industry
vs
history
P/E(ttm) 14.66
DGX's P/E(ttm) is ranked higher than
83% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.71 vs. DGX: 14.66 )
Ranked among companies with meaningful P/E(ttm) only.
DGX' s P/E(ttm) Range Over the Past 10 Years
Min: 9.09  Med: 17.3 Max: 31.26
Current: 14.66
9.09
31.26
Forward P/E 16.53
DGX's Forward P/E is ranked higher than
89% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.01 vs. DGX: 16.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 14.41
DGX's PE(NRI) is ranked higher than
84% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.41 vs. DGX: 14.41 )
Ranked among companies with meaningful PE(NRI) only.
DGX' s PE(NRI) Range Over the Past 10 Years
Min: 9.48  Med: 15.54 Max: 22.3
Current: 14.41
9.48
22.3
Price/Owner Earnings (ttm) 16.17
DGX's Price/Owner Earnings (ttm) is ranked higher than
80% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.37 vs. DGX: 16.17 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DGX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.27  Med: 27.87 Max: 129.96
Current: 16.17
12.27
129.96
P/B 2.55
DGX's P/B is ranked higher than
66% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.49 vs. DGX: 2.55 )
Ranked among companies with meaningful P/B only.
DGX' s P/B Range Over the Past 10 Years
Min: 1.85  Med: 2.46 Max: 4.31
Current: 2.55
1.85
4.31
P/S 1.60
DGX's P/S is ranked higher than
73% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.25 vs. DGX: 1.60 )
Ranked among companies with meaningful P/S only.
DGX' s P/S Range Over the Past 10 Years
Min: 1.03  Med: 1.35 Max: 2.18
Current: 1.6
1.03
2.18
PFCF 17.48
DGX's PFCF is ranked higher than
69% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.29 vs. DGX: 17.48 )
Ranked among companies with meaningful PFCF only.
DGX' s PFCF Range Over the Past 10 Years
Min: 8.25  Med: 13.89 Max: 21.76
Current: 17.48
8.25
21.76
POCF 12.82
DGX's POCF is ranked higher than
68% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.28 vs. DGX: 12.82 )
Ranked among companies with meaningful POCF only.
DGX' s POCF Range Over the Past 10 Years
Min: 6.99  Med: 10.94 Max: 14.48
Current: 12.82
6.99
14.48
EV-to-EBIT 10.86
DGX's EV-to-EBIT is ranked higher than
79% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.76 vs. DGX: 10.86 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 10.7 Max: 15.1
Current: 10.86
7.4
15.1
EV-to-EBITDA 9.03
DGX's EV-to-EBITDA is ranked higher than
75% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.60 vs. DGX: 9.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
DGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 8.8 Max: 11.9
Current: 9.03
6.2
11.9
PEG 3.40
DGX's PEG is ranked lower than
61% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.76 vs. DGX: 3.40 )
Ranked among companies with meaningful PEG only.
DGX' s PEG Range Over the Past 10 Years
Min: 0.81  Med: 1.53 Max: 5.02
Current: 3.4
0.81
5.02
Shiller P/E 21.23
DGX's Shiller P/E is ranked higher than
90% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 42.53 vs. DGX: 21.23 )
Ranked among companies with meaningful Shiller P/E only.
DGX' s Shiller P/E Range Over the Past 10 Years
Min: 14.39  Med: 19.81 Max: 38.66
Current: 21.23
14.39
38.66
Current Ratio 1.36
DGX's Current Ratio is ranked lower than
84% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. DGX: 1.36 )
Ranked among companies with meaningful Current Ratio only.
DGX' s Current Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.25 Max: 2.15
Current: 1.36
0.74
2.15
Quick Ratio 1.29
DGX's Quick Ratio is ranked lower than
77% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. DGX: 1.29 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.17 Max: 2.03
Current: 1.29
0.7
2.03
Days Inventory 6.98
DGX's Days Inventory is ranked higher than
94% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 90.15 vs. DGX: 6.98 )
Ranked among companies with meaningful Days Inventory only.
DGX' s Days Inventory Range Over the Past 10 Years
Min: 6.93  Med: 7.75 Max: 8.46
Current: 6.98
6.93
8.46
Days Sales Outstanding 47.46
DGX's Days Sales Outstanding is ranked higher than
68% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. DGX: 47.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.51  Med: 43.71 Max: 48.01
Current: 47.46
40.51
48.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.87
DGX's Dividend Yield is ranked higher than
76% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. DGX: 1.87 )
Ranked among companies with meaningful Dividend Yield only.
DGX' s Dividend Yield Range Over the Past 10 Years
Min: 0.6  Med: 0.82 Max: 2.46
Current: 1.87
0.6
2.46
Dividend Payout 0.27
DGX's Dividend Payout is ranked higher than
80% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. DGX: 0.27 )
Ranked among companies with meaningful Dividend Payout only.
DGX' s Dividend Payout Range Over the Past 10 Years
Min: 0.09  Med: 0.13 Max: 0.91
Current: 0.27
0.09
0.91
Dividend Growth (3y) 42.30
DGX's Dividend Growth (3y) is ranked higher than
91% of the 32 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DGX: 42.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
DGX' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.8 Max: 55.4
Current: 42.3
0
55.4
Forward Dividend Yield 1.90
DGX's Forward Dividend Yield is ranked higher than
69% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. DGX: 1.90 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 7.61
DGX's Yield on cost (5-Year) is ranked higher than
97% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. DGX: 7.61 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
DGX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.44  Med: 3.34 Max: 10.01
Current: 7.61
2.44
10.01
3-Year Average Share Buyback Ratio 3.30
DGX's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.70 vs. DGX: 3.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.9  Med: 1.9 Max: 0
Current: 3.3
-16.9
0

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.12
DGX's Price/Projected FCF is ranked higher than
82% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DGX: 1.12 )
Ranked among companies with meaningful Price/Projected FCF only.
DGX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 0.86 Max: 3.77
Current: 1.12
0.65
3.77
Price/DCF (Earnings Based) 1.34
DGX's Price/DCF (Earnings Based) is ranked higher than
75% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. DGX: 1.34 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.19
DGX's Price/Median PS Value is ranked lower than
64% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. DGX: 1.19 )
Ranked among companies with meaningful Price/Median PS Value only.
DGX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1.02 Max: 1.66
Current: 1.19
0.24
1.66
Earnings Yield (Greenblatt) (%) 9.25
DGX's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. DGX: 9.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DGX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 6.6  Med: 9.35 Max: 13.6
Current: 9.25
6.6
13.6
Forward Rate of Return (Yacktman) (%) 10.30
DGX's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.46 vs. DGX: 10.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
DGX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 10.1  Med: 16.45 Max: 26.3
Current: 10.3
10.1
26.3

More Statistics

Revenue (TTM) (Mil) $7,498
EPS (TTM) $ 5.71
Beta0.67
Short Percentage of Float5.12%
52-Week Range $59.66 - 86.85
Shares Outstanding (Mil)139.02

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 7,509 7,669 7,906
EPS ($) 5.11 5.40 5.74
EPS w/o NRI ($) 5.11 5.40 5.74
EPS Growth Rate
(3Y to 5Y Estimate)
2.97%
Dividends Per Share ($) 1.53 1.57 1.76
» More Articles for NYSE:DGX

Headlines

Articles On GuruFocus.com
7 Best Stocks For Value Investors This Week - 7/30/16 Aug 01 2016 
Companies Hit 52-Week Highs Jul 19 2016 
Royce Special Equity Multi-Cap Fund Mar 22 2016 
Baron Growth Fund New Purchases Part 3 Feb 08 2016 
Popular Guru Stocks With High, Growing Yield Feb 03 2016 
The Best Companies of the Medical Industry – September 2015 Sep 25 2015 
Brian Rogers Buys Occidental Petroleum, Tyco In Q2 Jul 16 2015 
Vermillion (VRML) Ovarian Cancer Test Mega-deal; Papa Murphy's Holdings (FRSH) and Wix (WIX) Strong Mar 18 2015 
Charles Brandes' Top Buys During Q4 Feb 11 2015 
A Look at John Hussman's Recent Additions to His Portfolio Feb 06 2015 

More From Other Websites
7 Healthy Dividend Stocks for Quality and Security Aug 30 2016
Quest Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : DGX-US : August 30,... Aug 30 2016
Rosche's Zika test gets FDA emergency-use authorization Aug 29 2016
Sonora Quest Laboratories and Safeway Expand Highest-Quality Diagnostic Testing to Greater Arizona Aug 29 2016
EpiPen goes generic Aug 29 2016
Quest Diagnostics: Strategic Initiatives & Tie-ups to Add Value Aug 23 2016
ETF’s with exposure to Quest Diagnostics, Inc. : August 18, 2016 Aug 18 2016
Quest Diagnostics Approved to Use Electronic Drug Test Process for Federally-Mandated Workforce by... Aug 18 2016
Quest Diagnostics Approved to Use Electronic Drug Test Process for Federally-Mandated Workforce by... Aug 18 2016
Quest Diagnostics Declares Quarterly Cash Dividend Aug 17 2016
Quest Diagnostics Declares Quarterly Cash Dividend Aug 17 2016
5 Big Stocks to Buy for Big Gains Aug 15 2016
Quest Diagnostics To Speak At The 18th Annual Pacific Crest Global Technology Leadership Forum Aug 05 2016
Quest Diagnostics To Speak At The Canaccord Genuity 36th Annual Growth Conference Aug 05 2016
Quest Diagnostics Launches New Digital Dementia Assessment Test to Aid Physicians' Assessment of... Aug 04 2016
Quest Diagnostics Launches New Digital Dementia Assessment Test to Aid Physicians' Assessment of... Aug 04 2016
Quest Diagnostics and AncestryDNA Collaborate to Expand Consumer DNA Testing Aug 03 2016
Quest Diagnostics and AncestryDNA Collaborate to Expand Consumer DNA Testing Aug 03 2016
QUEST DIAGNOSTICS INC Financials Jul 28 2016
Data Diagnostics Healthcare Technology Wins Two Gold Honors for Innovation in the 2016 Golden Bridge... Jul 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)